AndrewSatlinMD

PubMed

• 4 citations
  Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
  Trisha Suppes, Suresh Durgam, Susan G Kozauer, Richard Chen, Hassan D Lakkis, Robert E Davis, Andrew Satlin, Kimberly E Vanover, Sharon Mates, Roger S McIntyre, Mauric...> ;Bipolar Disorders. 2023 Sep 1
• 34 citations
  Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
  Joseph R. Calabrese, Suresh Durgam, Andrew Satlin, Kimberly E. Vanover, Robert E. Davis, Richard Chen, Susan Kozauer, Sharon Mates, Gary S. Sachs> ;The American Journal of Psychiatry. 2021 Sep 23
• 11 citations
  Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure
  Nisha A. Gilotra, Adam D. DeVore, Thomas J. Povsic, Allison G. Hays, Virginia S. Hahn, Tolu A. Agunbiade, Allison DeLong, Andrew Satlin, Richard Chen, Robert L. Davis,...> ;Circulation. Heart Failure. 2021 Aug 31
• 11 citations
  Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.
  John M. Kane, Suresh Durgam, Andrew Satlin, Kimberly E. Vanover, Richard Chen, Robert C. Davis, Sharon Mates> ;International Clinical Psychopharmacology. 2021 May 28
• 1 citations
  Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia.
  John Edwards, Andrew Satlin, Suresh Durgam, Robert E. Davis, Richard Chen, Sharon Mates, Christoph U. Correll> ;Cns Spectrums. 2021 Apr 1
• 1 citations
  Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial.
  Ian D'Souza, Suresh Durgam, Andrew Satlin, Robert E. Davis, Susan Kozauer, Richard Chen, Sharon Mates, Joseph R. Calabrese> ;Cns Spectrums. 2021 Apr 1
• 16 citations
  Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
  Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, Richard Chen, Andrew Satlin, Sharon Mates> ;Schizophrenia Research. 2021 Feb 1
• 30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study.
  Vanover, K.,Glass, S.,Kozauer, S.,Saillard, J.,Sanchez, J.,Weingart, M.,Mates, S.,Satlin, A.,Davis, R.> ;CNS Spectr. 2019 Mar 13
• 14 citations
  Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrom...
  Alexis Arzimanoglou, Jose A. Ferreira, Andrew Satlin, Omar Olhaye, Dinesh Kumar, Shobha Dhadda, Francesco Bibbiani> ;European Journal of Paediatric Neurology. 2019 Jan 1
• 25 citations
  Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, ran...
  Alexis Arzimanoglou, Jose A. Ferreira, Andrew Satlin, Shannon Mendes, Betsy Williams, David Critchley, Edgar Schuck, Ziad Hussein, Dinesh Kumar, Shobha Dhadda, Frances...> ;European Journal of Paediatric Neurology. 2016 May 1
• 45 citations
  The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
  Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., Satlin, A., Gellerfors, P., Osswald, G.,...> ;Journal of Alzheimer's disease : JAD. 2014 Aug 7
• 21 citations
  Development of perampanel in epilepsy
  Andrew Satlin, Lynn D. Kramer, Antonio Laurenza> ;Acta Neurologica Scandinavica. Supplementum. 2013 Mar 11
• 8 citations
  A double-blind, randomized, multicenter, dose-ranging study to evaluate the safety and efficacy of fospropofol disodium as an intravenous sedative for colonoscopy in h...
  Sergio D. Bergese, Poorvi Dalal, Rashmi Vandse, Andrew Satlin, Zhengning Lin, Keith A. Candiotti, Larry Cohen, Tong J. Gan> ;American Journal of Therapeutics. 2013 Mar 1
• 109 citations
  Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia
  David G. Harper, Edward G. Stopa, V. Kuo-LeBlanc, Ann C. McKee, Kentaro Asayama, Ladislav Volicer, Neil W. Kowall, Andrew Satlin> ;Brain. 2008 Jun 1
• 160 citations
  Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
  Yağız Üresin, Addison A. Taylor, Charles Kilo, Diethelm Tschöpe, Massimo Santonastaso, Ghionul Ibram, Hui Fang, Andrew Satlin> ;Journal of the Renin-Angiotensin-Aldosterone System. 2007 Dec 1
• 17 citations
  Dual inhibition of the renin system by aliskiren and valsartan
  Suzanne Oparil, Steven A Yarows, Samir Patel, Jack Zhang, Andrew Satlin> ;Lancet. 2007 Sep 29
• 321 citations
  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
  Suzanne Oparil, Steven A Yarows, Samir Patel, Hui Fang, Jack Zhang, Andrew Satlin> ;Lancet. 2007 Jul 21
• 69 citations
  Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.
  Matthew R. Weir, Christopher Bush, David R. Anderson, Jack Zhang, Deborah L. Keefe, Andrew Satlin> ;Journal of the American Society of Hypertension. 2007 Jul 1
• 40 citations
  Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension
  Paolo Verdecchia, Carlos Calvo, Volker Möckel, Lucy Keeling, Andrew Satlin> ;Blood Pressure. 2007 Jan 1
• 167 citations
  Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan
  James L. Pool, Roland E. Schmieder, Michel Azizi, Jean-Claude Aldigier, Andrzej Januszewicz, Walter Zidek, Yanntong Chiang, Andrew Satlin> ;American Journal of Hypertension. 2007 Jan 1
• 37 citations
  In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease
  Blaise deB. Frederick, In Kyoon Lyoo, Andrew Satlin, Kyung-Heup Ahn, Minue J. Kim, Deborah A. Yurgelun-Todd, Bruce M. Cohen, Perry F. Renshaw> ;Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry. 2004 Dec 1
• 77 citations
  Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease.
  David G. Harper, Edward G. Stopa, Ann C. McKee, Andrew Satlin, David Fish, Ladislav Volicer> ;Neurobiology of Aging. 2004 Jul 1
• Comments on "Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials" by Muller and associates.
  Andrew Satlin, Gerd Rosenkranz, Harald Pohlmann> ;Journal of Clinical Psychopharmacology. 2003 Dec 1
• 34 citations
  A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression
  Adam B. Burrows, Carl Salzman, Andrew Satlin, Kenneth Noble, Bruce G. Pollock, B A Tamara Gersh> ;Depression and Anxiety. 2002 Jan 1
• 30 citations
  Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline.
  Blaise deB. Frederick, Andrew Satlin, Lawrence L. Wald, John Hennen, Neil C. Bodick, Perry F. Renshaw> ;The American Journal of Geriatric Psychiatry. 2002 Jan 1
• Join now to see all